Andrew Clark, PhD
Andrew Clark, PhD, Board Chairman, independent consultant in the biotech industry. He received his Ph.D. in Neuroscience from St. Andrew's University and was a post-doctoral research fellow in neuro-pharmacology at the University of Oxford. He worked in London as a biotechnology analyst at Baring Securities. Dr. Clark co-founded Reabourne Ltd, an investment management business focused on small capitalization technology and biotechnology companies, acting as portfolio manager. He left Reabourne in 2003 following the sale of the business. He has held a number of non-executive directorships with life-science and investment companies which include Tepnel and Lifeline Scientific.
Clemens Doppler, PhD
Clemens Doppler, PhD, Board Member, serves as Managing Partner of Heidelberg Capital Private Equity since 2008. Prior to joining Heidelberg Capital, he was a director and partner at 3i group since 2000. Dr. Doppler has 10 years of international business experience in the pharma and biotech industries. He held positions at Boehringer Mannheim (now Roche) and served until 2000 in the executive team of ANAWA Laboratorien AG a life science Clinical Research Organization which was acquired 1997 by Canadian Phoenix International Life Science (now MDS Inc.). As well as serving on various boards, Dr. Doppler is a member of the German biotech analyst association DVFA and also a PhD fellow of the German Cancer Research Centre, DKFZ. Dr. Doppler holds degrees in marketing and economics and a MSc. in molecular biology from the University of Heidelberg.
Klaas de Boer
Klaas de Boer, Board Member, Managing Partner of Entrepreneurs Fund Management LLP, London, UK. He has spent nearly 20 years working with entrepreneurial (technology) companies in Europe, Israel and the US in the areas of finance, strategy and business development, the last 10 of which with Entrepreneurs Fund. Previously he established and managed a corporate venturing team at Vanenburg Group, and worked as a strategy consultant with McKinsey & Co. Mr. de Boer holds an MSc in Physics from Delft University of Technology and an MBA from INSEAD.
Roberto Barzi, Board Member, Managing Director at Fort Rock Capital, London, UK, a London-based investor focused on direct healthcare investments throughout Europe and the US. He has more than ten years experience in private equity, venture capital, and direct investing, including with the international investor 3i, where he was a leading member of the global healthcare group. Roberto Barzi previously worked in M&A in New York and London, at Greenhill, Lehman Brothers and Salomon Brothers. He holds an MBA from the Wharton School and a business degree from Universita' Bocconi, Italy. An Italian national, he lives in London.
Christopher Townsend, Board Member, is investment Director at Hansa Capital GmbH and a qualified solicitor. He is also a director of Ocean Wilsons Holdings Limited, a listed Bermudan investment company. He has an MA from Peterhouse, Cambridge and an MBA from London Business School. He has more than 15 years of private equity experience, having previously worked as a principal in the investment team at Coller Capital Limited and as a solicitor at Ashurst Morris Crisp.
Christian Leikert, Board Member, is Partner at Creathor Ventures GmbH, a Bad Homburg, Germany based advisor of venture capital funds investing in healthcare and technology companies. He has over 20 years’ experience in healthcare venture capital investing. Christian started his career at Future Capital AG, a venture capital firm founded by Aventis SA (now Sanofi SA) and the State of Hesse. He holds a masters degree in business administration from LMU Munich. He currently also serves on the boards of Blueprint Genetics Oy and Cevec Pharmaceuticals GmbH.